The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Improving the efficacy of bispecific antibodies in AML
Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, shares some insights into how the efficacy of bispecific antibodies can be improved in the treatment of acute myeloid leukemia (AML) from a pre-clinical perspective. Dr Subklewe highlights some findings which show that the addition of another bispecific antibody which translates a positive co-stimulatory molecule can enhance T-cell function, greatly improving the efficacy of this treatment regimen in AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
